Beta Bionics (BBNX) director receives 16,965-share restricted stock unit grant

Rhea-AI Filing Summary

Dearen Danny L. reported acquisition or exercise transactions in this Form 4 filing.

Beta Bionics, Inc. director Danny L. Dearen reported receiving an equity grant in the form of restricted stock units. On May 21, 2026, he was awarded 16,965 shares of common stock at a stated price of $0.00 per share under the company’s 2025 Equity Incentive Plan. After this award, his direct holdings increased to 32,209 shares of common stock. This is a compensation-related grant rather than an open-market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Dearen Danny L.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	16,965	$0.00	--

Holdings After Transaction: Common Stock — 32,209 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 16,965 shares Grant price: $0.00 per share Shares held after grant: 32,209 shares +1 more

4 metrics

RSU grant size 16,965 shares Restricted stock unit award on May 21, 2026

Grant price $0.00 per share Stated transaction price for RSU award

Shares held after grant 32,209 shares Direct common stock holdings post-transaction

Transaction count by type 1 acquisition Form 4 transaction summary

Key Terms

restricted stock unit, 2025 Equity Incentive Plan, Form 4

3 terms

restricted stock unit financial

"Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan."

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

2025 Equity Incentive Plan financial

"Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan."

Form 4 regulatory

"The Form 4 lists a transaction price of $0.00 per share."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dearen Danny L.

(Last) (First) (Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE CALIFORNIA 92618

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/21/2026		A		16,965(1)	A	$0	32,209	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan.

	/s/ Stephen Feider, Attorney-in-Fact	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Beta Bionics (BBNX) director Danny L. Dearen report?

Danny L. Dearen reported an acquisition of shares through an equity grant. He received 16,965 shares of Beta Bionics common stock as a restricted stock unit award, increasing his direct holdings to 32,209 shares after the transaction.

How many Beta Bionics (BBNX) shares were granted to Danny L. Dearen?

Danny L. Dearen was granted 16,965 shares of common stock. The award was structured as restricted stock units under Beta Bionics’ 2025 Equity Incentive Plan and did not involve an open-market purchase at a cash purchase price.

What are Danny L. Dearen’s Beta Bionics (BBNX) holdings after the Form 4 grant?

Following the reported grant, Danny L. Dearen holds 32,209 shares of Beta Bionics common stock directly. This figure reflects his position after receiving the 16,965-share restricted stock unit award disclosed in the Form 4 filing.

Was cash paid for the Beta Bionics (BBNX) shares granted to Danny L. Dearen?

No cash purchase was reported for these shares. The Form 4 lists a transaction price of $0.00 per share, indicating the 16,965 shares were received as a restricted stock unit grant under a company equity incentive plan.

Under which plan did Danny L. Dearen receive his Beta Bionics (BBNX) equity award?

The award was granted under Beta Bionics’ 2025 Equity Incentive Plan. The Form 4 footnote specifies that the 16,965-share transaction represents a restricted stock unit award made pursuant to this equity incentive plan.